Clinical trial NCT02565992: Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
Official title: Phase I Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma (VLA-011 CAPRA)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Melanoma
Keywords: Pembrolizumab
Coxsackievirus A21
melanoma
CAVATAK
CVA21
checkpoint inhibitor
Lead sponsor: Viralytics
Sponsor class: INDUSTRY
First posted: 2015-10-01
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will employ a phase Ib design using the established dose of CAVATAK with pembrolizumab in subjects with advanced melanoma for whom pembrolizumab would be considered standard of care. Our hypothesis is that oncolysis of melanoma cells by CAVATAK will be important in amplifying the T-cell potentiating effects of pembrolizumab.


Eligibility criteria: Inclusion Criteria:

* Subjects with metastatic or unresectable stage IIIb/c of IV melanoma for whom treatment with pembrolizumab is indicated and who have at least one cutaneous, subcutaneous tumor or palpable lymph node amenable to intratumoral injection.
* At least one tumor must qualify to be an index lesion for modified WHO criteria.
* Subjects must have adequate hematologic, hepatic and renal function.
* ECOG performance status of 0 or 1.
* Anticipated lifespan greater than 12 weeks

Exclusion Criteria:

* Ocular primary tumors.
* Presence of any central nervous system tumor that has not been stable for at least 4 weeks off corticosteroids.
* Tumors lying in mucosal regions or close to an airway, major blood vessel or spinal cord.
* Subjects with active, known or suspected autoimmune or immunosuppressive disease.
* Subjects previously treated with CVA21.
* Subjects requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days prior to the first treatment.
* Subject has received chemotherapy within the last 4 weeks prior to first treatment.
* Clinically significant cardiovascular disease.
* Females of childbearing potential must have negative serum or urine pregnancy test.
* Subjects requiring or using other investigational agents while on treatment in this trial.
* History of other malignancy within the last 3 years (with exceptions).
* Active infection requiring systemic therapy.
* Known history of HIV disease, active hepatitis B or hepatitis C.
* History or evidence of other clinically significant disorders that would pose a risk to subject safety.
* Inability to give informed consent and comply with the protocol.

Primary outcomes:
measure: The incidence of dose-limiting toxicities (DLT) of intravenous pembrolizumab in combination with intratumoral CAVATAK will be assessed using CTCAE v. 4.0.
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: John Wayne Cancer Institute
state: California
city: New Brunswick
country: United States
facility: Rutgers Cancer Institute of New Jersey
state: New Jersey
city: Canton
country: United States
facility: Gabrail Cancer Center Research
state: Ohio
Study officials:
References:
citation: Silk AW, O'Day SJ, Kaufman HL, Bryan J, Norrell JT, Imbergamo C, Portal D, Zambrano-Acosta E, Palmeri M, Fein S, Wu C, Guerreiro L, Medina D, Bommareddy PK, Zloza A, Fox BA, Ballesteros-Merino C, Ren Y, Shafren D, Grose M, Vieth JA, Mehnert JM. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. Cancer Immunol Immunother. 2023 Jun;72(6):1405-1415. doi: 10.1007/s00262-022-03314-1. Epub 2022 Nov 29.